의약품 수탁제조 시장 : 제조 제품 유형별, 원료의약품 유형별, 원료의약품 약리 활성별, FDF 유형별, 제형별, 포장 유형별, 사업 규모별, 최종사용자별, 지역별 : 산업 동향 및 세계 예측(-2035년)

Pharmaceutical Contract Manufacturing Market by Type of Product Manufactured, Type of API, API Potency, Type of FDF, Dosage Form, Type of Packaging Offered, Scale of Operation, End Users and Regions: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,618,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,653,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,618,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 의약품 수탁제조 시장 규모는 2035년까지 예측 기간 동안 4.3%의 CAGR로 확대되어 현재 990억 달러에서 2035년까지 1,560억 달러로 성장할 것으로 예상됩니다.

의약품 수탁제조 시장은 주로 제품 출시의 효율성과 유연성에 대한 수요로 인해 크게 성장하고 있습니다. 업무 전문성, 첨단 장비, 전문 시설 등의 요인으로 인해 아웃소싱이 증가하고 있습니다. 세계 CMO 및 CDMO에 제조 업무를 아웃소싱함으로써 기업은 공급망을 다변화하고 정치적, 경제적 불확실성에 따른 리스크를 줄일 수 있다는 점은 주목할 만합니다. 또한 자동화, 연속 생산, 데이터 분석과 같은 첨단 기술의 통합은 생산능력을 향상시키고 고품질의 결과를 보장합니다. 빠르게 진화하는 제약 산업에서 제약 위탁생산 업체들은 복잡한 규제 환경을 극복하고, 제조 워크플로우를 최적화하며, 임상시험에서 상업적 규모의 제조로 원활하게 전환할 수 있는 전문성을 보유하고 있습니다. 앞서 언급한 요인들은 예측 기간 동안 위탁 서비스 제공업체들에게 유리한 시장 성장 기회를 제공할 가능성이 높습니다.

본 보고서는 세계의 의약품 수탁제조 시장에 대해 조사했으며, 시장 개요와 함께 제조 제품 유형별, 원료의약품 유형별, 원료약리활성별, FDF 유형별, 제형별, 포장 유형별, 사업 규모별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 소개

제6장 의약품 수탁제조 : 규제 상황

제7장 의약품 수탁제조 : 시장 상황

제8장 지역별 능력

제9장 기업 개요

제10장 쇼트 프로파일

제11장 제조인가 구입인가 의사 의사결정 프레임워크

제12장 인수합병

제13장 최근의 확장

제14장 용량 분석

제15장 수요 분석

제16장 시장에 대한 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제17장 세계의 의약품 수탁제조 시장

제18장 의약품 수탁제조 시장(제조 제품 유형별)

제19장 원료의약품 수탁제조 시장(원료의약품 유형별)

제20장 원료의약품 수탁제조 시장(원료의약품 약리 활성별)

제21장 의약품 FDF 수탁제조 시장(FDF 유형별)

제22장 의약품 FDF 수탁제조 시장(제형별)

제23장 의약품 수탁제조 시장(포장 유형별)

제24장 의약품 수탁제조 시장(최종사용자별)

제25장 의약품 수탁제조 시장(사업 규모별)

제26장 의약품 수탁제조 시장(주요 지역별)

제27장 의약품 수탁제조 시장(주요 기업별)

제28장 사례 연구 : 저분자약과 고분자약/치료법의 비교

제29장 결론

제30장 이그제큐티브 인사이트

• 분석 개요
• Ajinomoto Althea
• Bachem
• CiVentiChem
• CordenPharma
• Helsinn Group
• Novasep
• Sovereign Pharma
• Wavelength Pharmaceuticals

제31장 부록 I : 표형식 데이터

제32장 부록 II : 기업 및 단체 리스트

ksm

영문 목차

영문목차

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global pharmaceutical contract manufacturing market is estimated to grow from USD 99 billion in the current year to USD 156 billion by 2035, at a CAGR of 4.3% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product Manufactured

• API & Intermediates
• FDF

Type of API

• Originator API
• Generic API

API Potency

• Low Potent API
• High Potent API

Type of FDF

• Originator FDF
• Generic FDF

Dosage Form

• Oral Solids
• Liquids
• Emulsions
• Other Dosage Forms

Type of Packaging Offered

• Bottles
• Blisters
• Parenteral
• Others

Scale of Operation

• Clinical
• Commercial

Type of End-user

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

The pharmaceutical contract manufacturing market is poised for significant growth, primarily driven by the demand for efficiency and flexibility in bringing products to the market. Factors such as operational expertise, advanced equipment and specialized facilities have led to an increase in outsourcing operations. It is worth highlighting that by outsourcing manufacturing operations to CMOs and CDMOs with a global footprint, companies can diversify their supply chains and reduce risks associated with political and economic uncertainties. Moreover, the integration of advanced technologies, such as automation, continuous manufacturing and data analytics, boosts production capabilities and ensures high-quality outcomes. With the rapidly evolving pharmaceutical landscape, contract manufacturers bring expertise in navigating complex regulatory frameworks, optimizing production workflows, and supporting a seamless transition from clinical studies to commercial scale manufacturing. The aforementioned factors are likely to present lucrative market growth opportunities for contract service providers during the forecast period.

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the pharmaceutical contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, close to 425 organizations offer pharmaceutical contract manufacturing services; of these, majority of the CMOs provide fill-finish / packaging and labelling services.

2. A relatively larger proportion of CMOs manufacture FDFs; close to 15% of the players have the required capabilities to manufacture all types of finished dosage forms.

3. In pursuit of building a competitive edge and to establish themselves as one-stop shops, stakeholders are actively consolidating their capabilities related to small molecule manufacturing through mergers and acquisitions.

4. In order to meet the rising demand for APIs and finished products, CMOs have made elaborate investments in expanding their existing capacities and capabilities; this trend is most pronounced in the US and India.

5. The global pharmaceutical contract manufacturing capacity is well distributed across different facilities worldwide; notably, large and very large players account for 80% of the total capacity.

6. Owing to the increase in outsourcing activity for small molecule manufacturing operations, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly over the decade.

7. In the past decade, a shift in trend has been observed in the pharmaceutical contract manufacturing industry as more players have set up their manufacturing facilities in developing regions across Asia-Pacific.

8. Driven by the increasing pace of expansions and mergers between the stakeholders in this domain, the market for pharmaceutical contract manufacturing is poised to witness steady growth in the foreseeable future.

9. The pharmaceutical contract manufacturing market is anticipated to grow at a steady rate, till 2035; North America is expected to capture the majority share (over 35%) of the market by 2035.

10. In the long term, small and mid-sized companies are likely to drive the growth of the pharmaceutical contract manufacturing market; oral solids is expected to capture the majority share (~50%) by 2035.

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

FDF segment is Likely to Dominate the Pharmaceutical Contract Manufacturing Market During the Forecast Period

Based on the type of product manufactured, the market is segmented into API & Intermediates and FDF. It is worth highlighting that majority of the current pharmaceutical contract manufacturing market is captured by the FDF segment and this trend is likely to remain the same in the forthcoming years. This can be attributed to the growing demand for ready-to-make products, high value addition and stringent regulatory guidelines.

Currently, Generic and Originator APIs Hold Similar Market Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of APIs, the market is segmented into generic API and originator API. It is worth highlighting that, at present, both generic and originator APIs capture almost similar market share in the pharmaceutical contract manufacturing market. This can be attributed to competitive pricing and quality standards maintained by generic manufacturers. It is worth noting that there is continued demand for branded drugs from originator companies.

High Potent API Segment is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market

Based on the types of API by potency, the market is segmented into low potent API and high potent API. Owing to their enhanced efficacy, lower dosage requirements and increasing demand for targeted therapies, the highly potent API (HPAPI) market is likely to grow at a relatively higher CAGR.

Currently, Originator FDF Occupies the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of FDFs, the market is segmented into generic FDF and originator FDF. Owing to brand loyalty, ongoing investments in research and development, and established market presence, the originator FDF holds the maximum share within the pharmaceutical contract manufacturing market.

Liquid Dosage Form is the Fastest Growing Segment of the Pharmaceutical Contract Manufacturing Market

Based on the dosage forms, the market is segmented into oral solids, liquids, emulsions and others. It is worth highlighting that, due to the simplicity of administration, growing applications in pediatric and geriatric populations and enhanced patient adherence, liquids are likely to grow at a higher CAGR in the forthcoming years.

Currently, Bottles Occupy the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of packaging offered, the market is segmented into bottles, blisters, parenterals and others. It is worth highlighting that, at present, bottles hold the maximum share within the pharmaceutical contract manufacturing market. Bottles offer various advantages, such as cost-effectiveness, versatility and capability to accommodate various types of formulations and dosages.

By Scale of Operation, Commercial Scale is Likely to Dominate the Pharmaceutical Contract Manufacturing Market

Based on the scale of operation, the market is segmented into clinical and commercial scale. Whilst commercial scale manufacturing will be the primary driver of the overall market, it is worth highlighting that the pharmaceutical contract manufacturing market at the clinical scale is likely to grow at a relatively higher CAGR.

Small Companies Account for the Largest Share of the Pharmaceutical Contract Manufacturing Market

Based on the type of end-user, the market is segmented into small, mid-sized, and large and very large companies. It is worth highlighting that, at present, small companies capture the highest share within the pharmaceutical manufacturing market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Majority share is expected to be captured by contract manufacturers based in North America. It is worth highlighting that over the years, the market for Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Pharmaceutical Contract Manufacturing Market

• AMRI Global
• Altasciences
• Cambrex
• Catalent
• DPT Laboratories
• Aenova
• Almac
• Corden Pharma
• Fresenius Kabi
• Glatt
• Hovione
• Recipharm
• Siegfried
• CMIC Group
• Nectar Lifesciences
• Syngene
• WuXi AppTec

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Former Director of Business Development, Ajinomoto Althea
• Former Chief Executive Officer, Bachem
• President and Chief Executive Officer, CiVentiChem
• Digitalization and Artificial Intelligence Manager, CordenPharma
• Former Director, Commercial Development, Helsinn Group
• Former Director, Pharmaceuticals Marketing, Novasep
• Director, Operations, Sovereign Pharma
• Former Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the pharmaceutical contract manufacturing market, focusing on key market segments, including [A] type of product manufactured, [B] type of API, [C] API potency, [D] type of FDF, [E] dosage form, [F] type of packaging offered, [G] scale of operation, [H] end users and [I] key geographical regions.
• Regulatory Landscape: A discussion on general regulatory guidelines across different countries, featuring an elaborative assessment of various CMOs in the pharmaceutical contract manufacturing industry, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
• Market Landscape: A comprehensive evaluation of companies involved in contract manufacturing of small molecules, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of manufacturer, [F] type of services offered, [G] type of finished dosage form manufactured, [H] type of packaging offered and [I] scale of operation.
• Regional Capability Analysis: A detailed analysis of the capabilities of pharmaceutical contract manufacturing facilities in different regions (North America, Europe, Asia-Pacific and the Rest of the World) across the globe.
• Company Profiles: In-depth profiles of key industry players in pharmaceutical contract manufacturing market, focusing on [A] company overviews, [B] manufacturing portfolio, [C] financial information, [D] recent developments and [E] an informed future outlook.
• Additional Insights: An insightful framework that emphasizes the key indicators and factors that need to be considered by pharmaceutical drug developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
• Merger and Acquisitions: A comprehensive examination of the various mergers and acquisitions, focusing on multiple relevant parameters, including [A] year of agreement, [B] type of agreement, [C] key value drivers of the deal, [D] most active players (in terms of number of agreements signed) and [E] geographical location of the companies. In addition, the chapter provides information on the financial terms of the deals (if available) in order to enumerate the deal multiples (in terms of annual revenues of the acquired firm (at the time of acquisition) and years of experience in this domain).
• Acquisitions: An analysis of acquisitions has taken place in the pharmaceutical contract manufacturing domain, since 2017.
• Capacity Analysis: Estimation of global pharmaceutical manufacturing capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size and [B] key geographical regions.
• Demand Analysis: Informed estimates of the annual commercial and clinical demand for small molecule drugs across key geographical regions.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What is the current global demand for small molecules?
• What percentage of the pharmaceutical manufacturing operations are presently outsourced?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Considerations
  • 2.6.1. Demographics
  • 2.6.2. Economic Factors
  • 2.6.3. Government Regulations
  • 2.6.4. Supply Chain
  • 2.6.5. COVID Impact / Related Factors
  • 2.6.6. Market Access
  • 2.6.7. Healthcare Policies
  • 2.6.8. Industry Consolidation
• 2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Types of Third-party Manufacturers
• 5.3. Overview of Pharmaceutical Contract Manufacturing
• 5.4. Evolution of Pharmaceutical Contract Manufacturing
  • 5.4.1. Traditional Pharmaceutical CMOs
  • 5.4.2. Modern Pharmaceutical CMOs
• 5.5. Need for Outsourcing in the Pharmaceutical Industry
• 5.6. Services Offered by CMOs
• 5.7. Key Considerations While Selecting a CMO
• 5.8. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
• 5.9. Recent Developments in the Pharmaceutical Contract Manufacturing Industry
  • 5.9.1. Integration of Artificial Intelligence
  • 5.9.2. Strategic Partnerships and Collaborations
    • 5.9.2.1. Strategic Long-Term Alliance
    • 5.9.2.2. Flexible Short-Term Partnership Agreements
  • 5.9.3. Integrated End-to-End Business Model
  • 5.9.4. Dependence on Software Service Providers
• 5.10. Future Perspectives

6. PHARMACEUTICAL CMOs: REGULATORY LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Regulatory Guidelines in North America
  • 6.2.1. Landscape in the US
  • 6.2.2. Landscape in Canadian
• 6.3. Regulatory Guidelines in Europe
• 6.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
  • 6.4.1. Landscape in China
  • 6.4.2. Landscape in India
  • 6.4.3. Landscape in Japan
  • 6.4.4. Landscape in South Korea
  • 6.4.5 Landscape in Australia
  • 6.4.6. Landscape in Brazil
• 6.5. Analysis of Pharmaceutical CMOs by Approval Received from Regulatory Authorities
• 6.6. Regulatory Landscape: Regional Benchmarking Analysis

7. PHARMACEUTICAL CMOs: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Pharmaceutical CMOs: List of Companies
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Location of Manufacturing Facility
  • 7.2.5. Analysis by Product Manufacturing Capability
  • 7.2.6. Analysis by Type of Product Manufactured
  • 7.2.7. Analysis by Type of Service Offered
  • 7.2.8. Analysis by Type of Finished Dosage Form Manufactured
  • 7.2.9. Analysis by Type of Packaging Offered
  • 7.2.10. Analysis by Scale of Operation

8. REGIONAL CAPABILITY

• 8.1. Chapter Overview
• 8.2. Key Assumptions and Methodology
• 8.3. Overall Landscape of Pharmaceutical Contract Manufacturing Facilities
  • 8.3.1. Pharmaceutical Contract Manufacturing Facilities in North America
  • 8.3.2. Pharmaceutical Contract Manufacturing Facilities in Europe
  • 8.3.3. Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific
  • 8.3.4. Pharmaceutical Contract Manufacturing Facilities in Rest of the World

9. COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. Pharmaceutical CMOs based in North America
  • 9.2.1. AMRI Global
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Service Portfolio
    • 9.2.1.3. Recent Developments and Future Outlook
  • 9.2.2. Altasciences
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Service Portfolio
    • 9.2.2.3. Recent Developments and Future Outlook
  • 9.2.3. Cambrex
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Service Portfolio
    • 9.2.3.3. Recent Developments and Future Outlook
  • 9.2.4. Catalent
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Information
    • 9.2.4.3. Service Portfolio
    • 9.2.4.4. Recent Developments and Future Outlook
  • 9.2.5. DPT Laboratories
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Service Portfolio
    • 9.2.5.3. Recent Developments and Future Outlook
• 9.3. Pharmaceutical CMOs based in Europe
  • 9.3.1. Aenova
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Information
    • 9.3.1.3. Service Portfolio
    • 9.3.1.4. Recent Developments and Future Outlook
  • 9.3.2. Almac
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Information
    • 9.3.2.3. Service Portfolio
    • 9.3.2.4. Recent Developments and Future Outlook
  • 9.3.3. CordenPharma
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Service Portfolio
    • 9.3.3.3. Recent Developments and Future Outlook
  • 9.3.4. Fresenius Kabi
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Information
    • 9.3.4.3. Service Portfolio
    • 9.3.4.4. Recent Developments and Future Outlook
  • 9.3.5. Glatt
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Service Portfolio
    • 9.3.5.3. Recent Developments and Future Outlook
  • 9.3.6. Hovione
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Service Portfolio
    • 9.3.6.3. Recent Developments and Future Outlook
  • 9.3.7. Recipharm
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Information
    • 9.3.7.3. Service Portfolio
    • 9.3.7.4. Recent Developments and Future Outlook
  • 9.3.8. Siegfried
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Information
    • 9.3.8.3. Service Portfolio
    • 9.3.8.4. Recent Developments and Future Outlook
• 9.4. Pharmaceutical CMOs based in Asia-Pacific and Rest of the World
  • 9.4.1. CMIC Group
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Information
    • 9.4.1.3. Service Portfolio
    • 9.4.1.4. Recent Developments and Future Outlook
  • 9.4.2. Nectar Lifesciences
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Information
    • 9.4.2.3. Service Portfolio
    • 9.4.2.4. Recent Developments and Future Outlook
  • 9.4.3. Syngene
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Information
    • 9.4.3.3. Service Portfolio
    • 9.4.3.4. Recent Developments and Future Outlook
  • 9.4.4. WuXi AppTec
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Information
    • 9.4.4.3. Service Portfolio
    • 9.4.1.4. Recent Developments and Future Outlook

10. SHORT PROFILES

• 10.1. Chapter Overview
• 10.2. Players based in North America
  • 10.2.1. Albemarle
  • 10.2.2. Baxter
  • 10.2.3. Patheon
  • 10.2.4. West Pharmaceutical Services
• 10.3. Players based in Europe
  • 10.3.1. Eurofins Scientific
  • 10.3.2. Evonik
  • 10.3.3. Fareva
  • 10.3.4. GlaxoSmithKline
  • 10.3.5. Lonza
• 10.4. Players based in Asia-Pacific and Rest of the World
  • 10.4.1. Alkem Laboratories
  • 10.4.2. Aspen Pharmacare
  • 10.4.3. MSN Laboratories
  • 10.4.4. Teva Pharmaceuticals
  • 10.4.5. UBE Corporation

11. MAKE VERSUS BUY DECISION FRAMEWORK

• 11.1. Chapter Overview
• 11.2. Assumptions and Key Parameters
• 11.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
  • 11.3.1. Scenario 1
  • 11.3.2. Scenario 2
  • 11.3.3. Scenario 3
  • 11.3.4. Scenario 4
• 11.4. Concluding Remarks

12. MERGERS AND ACQUISITIONS

• 12.1. Chapter Overview
• 12.2. Merger and Acquisition Models
• 12.3. Pharmaceutical Contract Manufacturing: Mergers and Acquisitions
  • 12.3.1. Analysis by Year of Agreement
  • 12.3.2. Analysis by Type of Agreement
  • 12.3.3. Analysis by Type of Acquisition
  • 12.3.4. Analysis by Focus Area
  • 12.3.5. Analysis by Type of Business Segment
  • 12.3.6. Analysis by Type of Service Offered
  • 12.3.7. Analysis by Scale of Operation
  • 12.3.8. Analysis by Geography
  • 12.3.9. Analysis by Location of Manufacturing Facility
  • 12.3.10. Analysis by Key Value Drivers
  • 12.3.11. Analysis by Year of Acquisition and Key Value Drivers
  • 12.3.12. Most Active Acquirers: Analysis by Number of Acquisitions
• 12.4. Key Acquisitions: Analysis by Deal Multiples

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Type of Expansions
• 13.2. Pharmaceutical CMOs: Recent Expansions
  • 13.2.1. Analysis by Year of Expansion
  • 13.2.2. Analysis by Type of Expansion
  • 13.2.3. Analysis by Purpose of Expansion
  • 13.2.4. Analysis by Year and Purpose of Expansion
  • 13.2.5. Analysis by Type of Business Segment
  • 13.2.6. Analysis by Type of API Manufactured
  • 13.2.7. Analysis by Type of Service Offered
  • 13.2.8. Analysis by Scale of Operation
  • 13.2.9. Analysis by Capital Invested
  • 13.2.10. Analysis by Location of Headquarters
  • 13.2.11. Analysis by Location of Manufacturing Facility
  • 13.2.12. Most Active Players: Analysis by Number of Recent Expansions

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Scale of Operation
  • 14.3.2. Analysis by Location of Headquarters
  • 14.3.3. Analysis by Location of Manufacturing Facilities
    • 14.3.3.1. Pharmaceutical Contract Manufacturing Capacity in North America
    • 14.3.3.2. Pharmaceutical Contract Manufacturing Capacity in Europe
    • 14.3.3.3. Pharmaceutical Contract Manufacturing Capacity in Asia-Pacific
• 14.4. Concluding Remarks

15. DEMAND ANALYSIS

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
  • 15.2.1. Overall Annual Demand for Small Molecule APIs, till 2035
  • 15.2.2. Annual Commercial Demand for Small Molecule APIs: Distribution by Geography, Current Year and 2035
    • 15.2.2.1. Annual Commercial Demand for Small Molecule APIs in North America, till 2035
    • 15.2.2.2. Annual Commercial Demand for Small Molecule APIs in Europe, till 2035
    • 15.2.2.3. Annual Commercial Demand for Small Molecule APIs in Asia-Pacific, till 2035
    • 15.2.2.4. Annual Commercial Demand for Small Molecule APIs in Rest of the World, till 2035
  • 15.2.3. Annual Clinical Demand for Small Molecule APIs: Distribution by Trial Phase, Current Year and 2035
    • 15.2.3.1. Annual Clinical Demand for Small Molecule APIs in Phase I Trials, till 2035
    • 15.2.3.2. Annual Clinical Demand for Small Molecule APIs in Phase II Trials, till 2035
    • 15.2.3.3. Annual Clinical Demand for Small Molecule APIs in Phase III Trials, till 2035
• 15.3. Annual Demand vs Capacity

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Assumptions and Methodology
• 17.3. Global Pharmaceutical Contract Manufacturing Market, Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 17.3.1. Scenario Analysis
    • 17.3.1.1. Conservative Scenario
    • 17.3.1.2. Optimistic Scenario
• 17.4. Key Market Segments

18. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT MANUFACTURED

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Product Manufactured, Current Year and 2035
  • 18.3.1. Pharmaceutical Contract Manufacturing Market for API and Intermediates: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 18.3.2. Pharmaceutical Contract Manufacturing Market for FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY TYPE OF API

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Pharmaceutical API Contract Manufacturing Market: Distribution by Type of API, Current Year and 2035
  • 19.3.1. Pharmaceutical API Contract Manufacturing Market for Generic API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 19.3.2. Pharmaceutical API Contract Manufacturing Market for Originator API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. PHARMACEUTICAL API CONTRACT MANUFACTURING MARKET, BY API POTENCY

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Pharmaceutical API Contract Manufacturing Market: Distribution by API Potency, Current Year and 2035
  • 20.3.1. Pharmaceutical API Contract Manufacturing Market for Low Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 20.3.2. Pharmaceutical API Contract Manufacturing Market for High Potent API: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY TYPE OF FDF

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Type of FDF, Current Year and 2035
  • 21.3.1. Pharmaceutical FDF Contract Manufacturing Market for Generic FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 21.3.2. Pharmaceutical FDF Contract Manufacturing Market for Originator FDF: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. PHARMACEUTICAL FDF CONTRACT MANUFACTURING MARKET, BY DOSAGE FORM

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Pharmaceutical FDF Contract Manufacturing Market: Distribution by Dosage Form, Current Year and 2035
  • 22.3.1. Pharmaceutical FDF Contract Manufacturing Market for Oral Solids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 22.3.2. Pharmaceutical FDF Contract Manufacturing Market for Liquids: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 22.3.3. Pharmaceutical FDF Contract Manufacturing Market for Emulsions: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 22.3.4. Pharmaceutical FDF Contract Manufacturing Market for Other Dosage Forms: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation

23. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF PACKAGING OFFERED

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Pharmaceutical Contract Manufacturing Market: Distribution by Type of Packaging Offered, Current Year and 2035
  • 23.3.1. Pharmaceutical Contract Manufacturing Market for Bottles: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 23.3.2. Pharmaceutical Contract Manufacturing Market for Blisters: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 23.3.3. Pharmaceutical Contract Manufacturing Market for Parenteral: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 23.3.4. Pharmaceutical Contract Manufacturing Market for Others: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END-USERS

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Pharmaceutical Contract Manufacturing Market: Distribution by End-users, Current Year and 2035
  • 24.3.1. Pharmaceutical Contract Manufacturing Market for Small Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 24.3.2. Pharmaceutical Contract Manufacturing Market for Mid-sized Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 24.3.3. Pharmaceutical Contract Manufacturing Market for Large and Very Large Companies: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 24.4. Data Triangulation and Validation

25. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Pharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, Current Year and 2035
  • 25.3.1. Pharmaceutical Contract Manufacturing Market for Clinical: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 25.3.2. Pharmaceutical Contract Manufacturing Market for Commercial: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 25.4. Data Triangulation and Validation

26. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. Pharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, Current Year and 2035
  • 26.3.1. Pharmaceutical Contract Manufacturing Market in North America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 26.3.2. Pharmaceutical Contract Manufacturing Market in Europe: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 26.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 26.3.2. Pharmaceutical Contract Manufacturing Market in Latin America: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
  • 26.3.3. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa: Historical Trends (since 2017) and Forecasted Estimates (till 2035)
• 26.4. Data Triangulation and Validation

27. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. Pharmaceutical Contract Manufacturing Market, by Leading Players
• 27.4. Data Triangulation and Validation

28. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES

• 28.1. Chapter Overview
• 28.2. Small Molecule and Large Molecule Drugs / Therapies
  • 28.2.1. Comparison of General Characteristics
  • 28.2.2. Comparison of Key Specifications
  • 28.2.3. Comparison of Manufacturing Processes
  • 28.2.4. Comparison of Key Manufacturing-related Challenges

29. CONCLUDING REMARKS

30. EXECUTIVE INSIGHTS

• 30.1. Chapter Overview
• 30.2. Ajinomoto Althea
  • 30.2.1. Company Snapshot
  • 30.2.2. Interview Transcript: Scott Goldstein, Former Director of Business Development
• 30.3. Bachem
  • 30.3.1. Company Snapshot
  • 30.3.2. Interview Transcript: Thomas Fruh, Former Chief Executive Officer
• 30.4. CiVentiChem
  • 30.4.1. Company Snapshot
  • 30.4.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
• 30.5. CordenPharma
  • 30.5.1. Company Snapshot
  • 30.5.2. Interview Transcript: Roberto Margartia, Digitalization and Artificial Intelligence Manager
• 30.6. Helsinn Group
  • 30.6.1. Company Snapshot
  • 30.6.2. Interview Transcript: Allison Vavala, Former Director, Commercial Development
• 30.7. Novasep
  • 30.7.1. Company Snapshot
  • 30.7.2. Interview Transcript: Kevin Daley, Former Director, Pharmaceuticals Marketing
• 30.8. Sovereign Pharma
  • 30.8.1. Company Snapshot
  • 30.8.2. Interview Transcript: Piyush Desai, Director, Operations
• 30.9. Wavelength Pharmaceuticals
  • 30.9.1. Company Snapshot
  • 30.9.2. Interview Transcript: Ilan Avni, Former Vice President Business Development, Marketing, and IP

31. APPENDIX I: TABULATED DATA

32. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료